CloneID: I-81C6 (Neuradiab)
Antigen Long Description: This therapeutic antibody was generated by radiolabelling, using a modified Iodo-gen procedure, murine anti-human tenascin Mab 81C6. Mab 81C6 was raised by immunizing mice with the glial fibrillary acidic protein-positive human glioma cell line U-251 MG (Bourdon et al, 1983).
Buffer Composition: PBS only.
Uniprot Accession No.: P24821
Specificity Statement: This antibody is specific for tenascin, which is expressed in restricted locations in normal adult liver, kidney, spleen, and papillary dermis. However, tenascin has been shown to have increased stromal expression in breast carcinomas, gliomas, and prostatic carcinomas. Consequently, this antibody reacts with most human glioma cell lines, xenografts, and biopsy tissue, but not with normal brain tissue.
Application Notes (Clone): This I-labelled murine antibody binds tenascin, which is over expressed in certain cancers, and as a result has been used to deliver a radiation boost to the surgically created resection cavity (SCRC) margin; administration of a patient-specific radioactivity dose of this antibody into the SCRC enabled the consistent achievement of a 44-Gy boost to the SRC 2cm margin, associated with reduced neurotoxicity and improved survival relative to fixed dosing approaches (Reardon, 2008). In addition, a humanized form of this I-labeled murine antibody, generated by joining the 81C6 variable regions to the constant region of human IgG2, has been characterised through binding assays, cross-competition assays and immunoreactivity analysis, and has exhibited superior uptake in human glioma xenografts compared with its murine 81C6 parent (Zalutsky, 1996).